Peroxisome proliferator-activated receptor-γ agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease
- 30 June 2004
- journal article
- clinical trial
- Published by Elsevier BV in American Heart Journal
- Vol. 147 (6), 1032-1037
- https://doi.org/10.1016/j.ahj.2003.12.035
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Circulating Monocyte-Platelet Aggregates Are a More Sensitive Marker of In Vivo Platelet Activation Than Platelet Surface P-SelectinCirculation, 2001
- Modulation of Vascular Inflammation In Vitro and In Vivo by Peroxisome Proliferator–Activated Receptor-γ ActivatorsCirculation, 2000
- Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trialJournal of the American College of Cardiology, 1999
- In Vivo Formation of 8-Iso-Prostaglandin F 2α and Platelet Activation in Diabetes MellitusCirculation, 1999
- Role of activation-dependent platelet membrane glycoproteins in development of subacute occlusive coronary stent thrombosisCoronary Artery Disease, 1997
- Flow cytometric analysis of platelet activation markers CD62P and CD63 in patients with coronary artery diseaseEuropean Journal of Clinical Investigation, 1996
- The Pathogenesis of Coronary Artery Disease and the Acute Coronary SyndromesNew England Journal of Medicine, 1992
- Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in manDiabetologia, 1985
- Fibrin formation and platelet aggregation in patients with severe coronary artery disease: relationship with the degree of myocardial ischemia.Circulation, 1985
- Platelet Functions in Diabetes MellitusDiabetes, 1978